- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01325766
Study of Yoga as a Therapy for Cystic Fibrosis (CF) Patients
Yoga as a Therapy for Adolescents and Young Adults With Cystic Fibrosis: A Pilot Study
Cystic fibrosis (CF) is a lung disease that affects 30,000 children and adults in the US. Incorporation of regular exercise into the lives of patients with CF is of interest because it may improve lung function and quality of life. Yoga is an activity that may benefit patients with CF in many ways including strengthening muscles of breathing, improving lung function, and reducing stress which could improve quality of life and adherence to therapies. Yoga has been shown to be beneficial in patients with other lung diseases such as asthma, but has not yet been studied in CF.
The investigators hypothesize that yoga will be an activity that is safe and tolerable for CF patients 12 to 25 years of age. The primary aim is to investigate the safety and tolerability of an 8 week yoga program for patients with CF. The secondary aim is to determine the effect of yoga on many aspects of CF disease including respiratory symptoms, adherence to regular CF therapies, quality of life, lung function, exercise tolerance, and nutritional status.
The long-term goal is to use the data obtained in this study to design a future study of the efficacy of yoga in a larger population of CF patients at multiple CF centers. This research has the potential to influence the prevention and treatment of CF by providing data which could be used to help understand the most appropriate and beneficial type of physical activity for CF patients.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Seattle Children's Hospital
-
Principal Investigator:
- Jennifer Ruddy, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
o Diagnosis of CF by: Sweat chloride ≥60meq/L on two occasions or CFTR genotype with two CF disease-causing mutations and one or more phenotypic features of CF
- Age ≥12 and ≤25 years
- FEV1 ≥40 % predicted at screening visit
- Informed consent and assent
Exclusion Criteria:
- Wheezing on auscultation of the chest at the enrollment visit
- Oxygen saturation < 90 % at the enrollment visit
- Initiation of treatment with oral, inhaled or intravenous antibiotics for an acute respiratory infection in the 2 weeks preceding the enrollment visit
- Pregnancy
- History of lung transplant
- Practiced yoga regularly (≥1 time per week) in the month prior to enrollment
- Current enrollment in a therapeutic clinical trial
- Condition or situation which, in the opinion of the investigator, would affect the ability of the patient or family to complete study procedures
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Yoga (immediate start) group
This arm will start yoga sessions immediately after screening and will continue sessions for 8 weeks.
This group will then continue with home yoga for an additional 8 weeks.
|
Yoga 2 sessions per week for 8 weeks
|
Active Comparator: Yoga (waitlist) group
This arm will continue regular CF therapies for 8 weeks and will start yoga sessions at week 9.
|
Yoga 2 sessions per week for 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety
Time Frame: 16 weeks
|
Determine if a yoga program is safe for CF patients by monitoring for adverse events throughout the study.
|
16 weeks
|
Pain Scores on the Visual Analog Scale as a measure of tolerability
Time Frame: 16 weeks
|
Participants will be given a tolerance questionnaire after each yoga session which will assess their degree of musculoskeletal and chest pain on a visual analog scale.
Vital signs will also be measured before and after each yoga session.
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life
Time Frame: 16 weeks
|
This will be assessed with the Cystic fibrosis quality of life questionnaire-revised.
This is a CF specific quality of life outcome measure and will be administered at each study visit.
|
16 weeks
|
Respiratory symptoms
Time Frame: 16 weeks
|
This will be assessed using a cystic fibrosis respiratory symptom diary that will taken once per week at home throughout the study.
|
16 weeks
|
Treatment adherence
Time Frame: 16 weeks
|
This will be assessed by participants taking a treatment adherence questionnaire once per week at home.
Questions are asked regarding compliance with other CF therapies.
|
16 weeks
|
Pulmonary function
Time Frame: 16 weeks
|
Pulmonary function will be monitored by spirometry at the screening visit and at both study visits.
Participants will be assessed for response to bronchodilator at the screening visit.
If there is a positive response, post-bronchodilator testing will be done again at the last study visit.
|
16 weeks
|
Ease of breathing
Time Frame: 16 weeks
|
This will be assessed by the ease of breathing score which is a measure of shortness of breath after activity.
This will be done at screening and at each study visit.
|
16 weeks
|
BMI
Time Frame: 16 weeks
|
BMI will be assessed at each study visit.
|
16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jennifer Ruddy, MD, Seattle Children's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13424
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
-
University Hospital, BordeauxCompleted
Clinical Trials on Yoga
-
Universität Duisburg-EssenCompleted
-
University of Texas at AustinCompleted
-
Adiyaman University Research HospitalCompletedDepression | Stress | Anxiety | Psychological ResilienceTurkey
-
NMP Medical Research InstituteYog-Kulam; Department of Zoology, University of Rajasthan, IndiaCompleted
-
NMP Medical Research InstituteWarwick Research Services; Yog-KulamCompleted
-
Northwestern UniversityCompleted
-
University of MinnesotaCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedDepression | Pain | Breast Cancer | FatigueUnited States
-
Bartın UnıversityCompletedAsthma in Children | Telerehabilitation | YogaTurkey
-
Colorado State UniversityCompleted